Dual-tracer PET/CT can ID those who need liver transplant

01/21/2013 | AuntMinnie.com (free registration)

PET/CT imaging using combined carbon-11 acetate and FDG performed better than contrast-enhanced CT in diagnosing hepatocellular carcinoma and staging tumors in liver transplant patients and in partial hepatectomy cases, according to a study in the Journal of Nuclear Medicine. The dual-tracer PET/CT method identified HCC lesions in 94% of liver transplant patients and in 96% of partial hepatectomy patients. In terms of tumor-nodal-metastasis staging, the dual method showed 91% accuracy for the liver transplant group and 90% for the partial hepatectomy group. Overall, the method demonstrated 97% sensitivity and 92% specificity for patient selection for liver transplantation. "The inclusion of dual-tracer PET/CT in pretransplant workup may warrant serious consideration" in improving the determination of patients who are the most in need of a liver transplant, the researchers said.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA